Analyst Ratings February 9, 2026

TD Cowen Lifts Dynatrace Price Target to $60 After Strong ARR Momentum

Analyst keeps a Buy rating as recurring revenue growth, guidance bump and a $1 billion buyback underpin an attractive valuation

By Hana Yamamoto DT
TD Cowen Lifts Dynatrace Price Target to $60 After Strong ARR Momentum
DT

TD Cowen raised its price target on Dynatrace Inc. (DT) to $60 from $55 while retaining a Buy rating following a quarter of robust net new annual recurring revenue and improved ARR guidance. The upgrade reflects sustained ARR expansion, stable net revenue retention, a new $1 billion share repurchase program and fiscal-quarter results that topped earnings and revenue estimates.

Key Points

  • TD Cowen raised Dynatrace’s price target to $60 from $55 and kept a Buy rating, implying about 64% upside from the recent price of $36.49.
  • Dynatrace reported $75 million in NNARR, above expectations, marking 11% year-over-year growth and the third consecutive quarter of double-digit NNARR growth; overall revenue grew 18.5% over the last twelve months.
  • Company announced a $1 billion share repurchase program; valuation cited as roughly 15 times enterprise value to calendar year 2027 estimated free cash flow.

TD Cowen has revised its target price for Dynatrace Inc. (DT) upward to $60.00 from $55.00 and continues to carry a Buy recommendation on the provider of software intelligence. The new target implies substantial upside relative to the recent market price of $36.49, and consensus analyst projections point to roughly a 64% potential increase from current levels.

The firm’s adjustment follows Dynatrace’s report of $75 million in net new annual recurring revenue (NNARR) for the quarter, a figure that exceeded the low-$70 million expectation and represented 11% year-over-year growth. That marked the company’s third straight quarter of double-digit NNARR expansion and supports a 12-month revenue growth rate of 18.5%.

TD Cowen highlighted two main contributors to the stronger-than-expected ARR performance: a record level of new logo ARR and durable expansions within the installed base. Those dynamics led Dynatrace to raise its fiscal year ARR guidance by 125 basis points on a constant currency basis.

Net revenue retention (NRR) for the company remained steady at 111% for the period. TD Cowen’s analysts believe that NRR should improve by fiscal year 2027 as cohorts of the Dynatrace Platform Subscription (DPS) renew, though the firm maintained current estimates pending that cohort-driven improvement.

In addition to top-line momentum, Dynatrace announced a new $1 billion share buyback program. TD Cowen characterized the buyback as a signal of management confidence and flagged the company’s valuation as compelling - roughly 15 times enterprise value to estimated free cash flow for calendar year 2027.

Market-technical indicators noted in the company’s profile indicate the stock has recently been under upward pressure from an oversold reading, with the share price falling 11.41% over the past week and relative strength metrics in oversold territory. Additional analytical material referenced for investors includes 11 further insights and extended research coverage on Dynatrace, with visualized research on more than 1,400 prominent equities available through specialized Pro research services.

Dynatrace also reported solid results for the third quarter of fiscal 2026, beating analyst expectations on both the bottom and top lines. The company posted adjusted earnings per share of $0.44, above the forecast of $0.41, while quarterly revenue reached $515 million versus an anticipated $505.8 million. These results underscore the operating strength cited by analysts in support of the higher price target and Buy rating.

Taken together, the combination of above-consensus NNARR, an upgraded ARR outlook, steady NRR against the backdrop of anticipated cohort renewals, a material buyback authorization and better-than-expected quarterly results shaped TD Cowen’s reassessment of Dynatrace’s near-term value proposition.


What this means for investors

  • Analysts now see meaningful upside to the share price based on improved recurring revenue dynamics and attractive forward free cash flow multiples.
  • The buyback program and upgraded guidance contribute to a more favorable risk-reward profile in the view of the covering analyst.
  • Recent earnings and revenue beats provide operational confirmation of ARR strength.

Observations and caveats

  • NRR has held at 111% this quarter; meaningful improvement is expected only as DPS cohorts come up for renewal in fiscal 2027.
  • Technical indicators show the stock recently moved into oversold readings after an 11.41% decline in the past week, which may influence near-term price action.

Bottom line

TD Cowen’s $60 price target on Dynatrace rests on recurring revenue momentum, management’s capital return decision and valuation metrics calibrated against estimated free cash flow in 2027. The firm retains a Buy stance ahead of what it views as an improving NRR profile and continued expansion in ARR cohorts.

Risks

  • Net revenue retention remained flat at 111% this quarter - improvement is expected only when Dynatrace Platform Subscription cohorts renew in fiscal year 2027, introducing timing risk for revenue-quality improvements.
  • Recent share-price weakness and oversold technical indicators - a recent 11.41% weekly decline may signal short-term volatility that could affect market perception and liquidity.
  • Guidance and valuation assumptions rely on future free cash flow estimates for calendar year 2027, which are subject to execution and macroeconomic uncertainty that would impact software and enterprise IT spending.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026